CUE HEALTH INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.134 USD | +2.29% |
|
-4.50% | -17.72% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -17.72% | 20.84M | C | ||
| +9.41% | 3,051B | C+ | ||
| +6.53% | 83.97B | B | ||
| +4.83% | 76.9B | B+ | ||
| -13.91% | 54B | B+ | ||
| +23.93% | 48.01B | D+ | ||
| -24.44% | 46.47B | B- | ||
| +22.53% | 42.04B | D+ | ||
| +63.31% | 38.34B | D+ | ||
| -32.05% | 24.97B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HLTH Stock
- Ratings Cue Health Inc.